Can zinc levels predict response to pegylated-interferon and ribavirin therapy in hepatitis c genotype 4 infected Egyptian patients?

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorMohamed A.A.
dc.contributor.authorAbbassi M.M.
dc.contributor.authorHamed W.A.
dc.contributor.authorEzzel-Arab M.A.
dc.contributor.authorAref A.M.
dc.contributor.otherBiochemistry Department
dc.contributor.otherNational Hepatology and Tropical Medicine Research Institute
dc.contributor.otherCairo
dc.contributor.otherEgypt; Clinical Pharmacy Department
dc.contributor.otherCairo University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Tropical Medicine Department
dc.contributor.otherAin Shams University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Internal Medicine Department
dc.contributor.otherNational Hepatology and Tropical Medicine Research Institute
dc.contributor.otherCairo
dc.contributor.otherEgypt; Biotechnology Department
dc.contributor.otherMSA University
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:42:18Z
dc.date.available2020-01-09T20:42:18Z
dc.date.issued2014
dc.descriptionScopus
dc.descriptionMSA Google Scholar
dc.description.abstractBackground and Aims: Zinc has been found to be low in chronic hepatitis patients. Its level was correlated with response to Interferon/ribavirin therapy in patients infected with hepatitis C genotype 1. In Egypt, inexpensive predictors to treatment response in Hepatitis C genotype 4 infected patients are desperately needed. We aim to explore if pretreatment zinc serum levels correlate with response to pegylated- interferon and ribavirin therapy in Egyptian patients. Methods: This is an observational prospective study where 57 treatment na�ve hepatitis C genotype 4 infected patients that were Hepatitis B and Human Immunodeficiency virus negative were recruited in a hospital setting. The study was performed from October 2010 till June 2012. Patients had Liver biopsy and basic biochemical profiles were performed pretreatment for all patients. Treatment consisted of 48 weeks of pegylated-interferon-alpha2a and ribavirin therapy. Blood samples were withdrawn from 21 healthy subjects to compare zinc levels and other biochemical markers. Patients were followed up to 72 weeks. Results: Pretreatment serum zinc levels were significantly lower in hepatitis C infected patients compared to healthy volunteers (p < 0.05). Moreover, zinc levels correlated to sustained virological response in treated patients (p = 0.00). Conclusion: Serum zinc levels can be used as an inexpensive predictor to effective Pegylated-interferon/ribavirin therapy in Egyptian patients infected with Hepatitic C genotype 4.en_US
dc.identifier.issn15644
dc.identifier.urihttps://t.ly/OXXEL
dc.language.isoEnglishen_US
dc.publisherUniversa Pressen_US
dc.relation.ispartofseriesActa Gastro-Enterologica Belgica
dc.relation.ispartofseries77
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectMSA University
dc.subjectUniversity for Modern Sciences and Arts
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectAnd Egypt introductionen_US
dc.subjectGenotype 4en_US
dc.subjectHepatitis Cen_US
dc.subjectZincen_US
dc.subjectAdulten_US
dc.subjectAntiviral Agentsen_US
dc.subjectDrug Monitoringen_US
dc.subjectDrug Therapy, Combinationen_US
dc.subjectEgypten_US
dc.subjectFemaleen_US
dc.subjectGenotypeen_US
dc.subjectHepacivirusen_US
dc.subjectHepatitis C, Chronicen_US
dc.subjectHumansen_US
dc.subjectInterferon-alphaen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPolyethylene Glycolsen_US
dc.subjectPredictive Value of Testsen_US
dc.subjectProspective Studiesen_US
dc.subjectRecombinant Proteinsen_US
dc.subjectRibavirinen_US
dc.subjectYoung Adulten_US
dc.subjectZincen_US
dc.titleCan zinc levels predict response to pegylated-interferon and ribavirin therapy in hepatitis c genotype 4 infected Egyptian patients?en_US
dc.typeArticleen_US
dcterms.isReferencedByLin, C.C., Huang, J.F., Tsai, L.Y., Huang, Y.L., Selenium, iron, copper, and zinc levels and copper-to-zinc ratios in serum of patients at different stages of viral hepatic diseases (2006) Biol. Trace. Elem. Res, 109, pp. 15-24; Loguercio, C., Girolamo, V., Federico, A., Trace elements and chronic liver diseases (1997) J. Trace. Elem. Med. Biol, 11, pp. 158-161; Nazari, M.A., Malayeri, S.H., Pourhoseingholi, M.A., Mohebi, S.R., Zali, M.R., Evaluation of Zinc Plasma Level in Iranian Cirrhotic Patients due to Hepatitis B and Hepatitis C (2010) Hepat. Mon, 10, pp. 62-6411; Vallee, B.L., Auld, D.S., Cocatalytic zinc motifs in enzyme catalysis (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 2715-2718; Novick, S.G., Godfrey, J.C., Pollack, R.L., Wilder, H.R., Zincinduced suppression of inflammation in the respiratory tract, caused by infection with human rhinovirus and other irritants (1997) Med. Hypotheses, 49, pp. 347-357; Prasad, A.S., Zinc: Role in immunity, oxidative stress and chronic inflammation (2009) Curr. Opin. Clin. Nutr. Metab. Care, 12, pp. 646-652; Haraguchi, Y., Sakurai, H., Hussain, S., Anner, B.M., Hoshino, H., Inhibition of HIV-1 infection by zinc group metal compounds (1999) Antiviral Res, 43, pp. 123-133; Kumel, G., Schrader, S., Zentgraf, H., Brendel, M., Therapy of banal HSV lesions: Molecular mechanisms of the antiviral activity of zinc sulfate (1991) Hautarzt, 42, pp. 439-445; Suara, R.O., Crowe Jr., J.E., (2004) Effect of Zinc Salts On Respiratory Syncytial Virus Replication. Antimicrob. Agents Chemother, 48, pp. 783-790; Yuasa, K., Naganuma, A., Sato, K., Zinc is a negative regulator of hepatitis C virus RNA replication (2006) Liver Int, 26, pp. 1111-1118; Berg, K., Bolt, G., Andersen, H., Owen, T.C., Zinc potentiates the antiviral action of human IFN-alpha tenfold (2001) J Interferon Cytokine Res, 21, pp. 471-474; Salas, M., Kirchner, H., Induction of interferon-gamma in human leukocyte cultures stimulated by Zn2+ (1987) Clin. Immunol. Immunopathol, 45, pp. 139-142; Cakman, I., Kirchner, H., Rink, L., Zinc supplementation reconstitutes the production of interferon-alpha by leukocytes from elderly persons (1997) J. Interferon Cytokine Res, 17, pp. 469-472; Umeta, M., West, C.E., Haidar, J., Deurenberg, P., Hautvast, J.G., Zinc supplementation and stunted infants in Ethiopia: A randomised controlled trial (2000) Lancet, 355, pp. 2021-2026; Evans, G.W., Zinc and its deficiency diseases (1986) Clin. Physiol. Biochem, 4, pp. 94-98; Ko, W.S., Guo, C.H., Hsu, G.S., The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin (2005) Clin. Biochem, 38, pp. 614-620; Grungreiff, K., Abicht, K., Kluge, M., Clinical studies on zinc in chronic liver diseases (1988) Z Gastroenterol, 26, pp. 409-415; Solis-Herruzo, J., Cuenca, B.D., Munoz-Rivero, M.C., Intestinal zinc absorption in cirrhotic patients (1989) Z Gastroenterol, 27, pp. 335-338; Loguercio, C., Federico, A., Masarone, M., The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis (2008) Am. J. Gastroenterol, 103, pp. 3159-3166; Nagamine, T., Takagi, H., Hashimoto, Y., The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatitis C patients (1997) Biol. Trace. Elem. Res, 58, pp. 65-76; Ozbal, E., Helvaci, M., Kasirga, E., Akdenizoglu, F., Kizilgunesler, A., Serum zinc as a factor predicting response to interferon-alpha2b therapy in children with chronic hepatitis B (2002) Biol. Trace Elem. Res, 90, pp. 31-38; Selimoglu, M.A., Aydogdu, S., Unal, F., Yuce, G., Yagci, R.V., Serum zinc status in chronic hepatitis B and its relationship to liver histology and treatment results (2001) Pediatr. Int, 43, pp. 396-399; Takagi, H., Nagamine, T., Abe, T., Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C (2001) J. Viral Hepat, 8, pp. 367-371; Kim, K.I., Kim, S.R., Sasase, N., Blood cell, liver function, and response changes by PEG-interferon-alpha2b plus ribavirin with polaprezinc therapy in patients with chronic hepatitis C (2008) Hepatol. Int, 2, pp. 111-115; Murakami, Y., Koyabu, T., Kawashima, A., Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin (2007) J. Nutr. Sci. Vitaminol. (Tokyo), 53, pp. 213-218; Suzuki, H., Takagi, H., Sohara, N., Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: A randomized controlled clinical trial (2006) World. J. Gastroenterol, 12, pp. 1265-1269; Kamal, S.M., Nasser, I.A., Hepatitis C genotype 4: What we know and what we don't yet know (2008) Hepatology, 47, pp. 1371-1383; El-Zanaty, F., Way, A., (2012) Egypt Demographic and Health Survey 2009, Ministry of Health, , http://pdf.usaid.gov/pdf_docs/PNADO806.pdf, El-Zanaty and Associates, and Macro International, Accessed April; Sayed, N.E., Kandeel, A., Genedy, M., Progress Toward Prevention and Control of Hepatitis C Virus Infection - Egypt, 2001-2012 (2012) Morbidity and Mortality Weekly Report: U.S. Department of Health and Human Services, pp. 545-548. , Centers for Disease Control Prevention; Lee, S.S., Abdo, A.A., Predicting antiviral treatment response in chronic hepatitis C: How accurate and how soon? (2003) J. Antimicrob. Chemother, 51, pp. 487-491; Hadziyannis, S.J., Sette, H.J.R., Morgan, T.R., Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose (2004) Ann. Intern. Med, 140, pp. 346-355; Manns, M.P., McHutchison, J.G., Gordon, S.C., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial (2001) Lancet, 358, pp. 958-965; Lopez-Alonso, G., Agreda, M., Devesa, M.J., Results of the treatment of chronic hepatitis C genotype 4. A comparative analysis with genotype 1 (2008) Rev. Esp. Enferm. Dig, 100, pp. 208-211; (1964), http://www.wma.net/en/30publications/10policies/b3/, World Medical Association. Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. In: World Medical Association, (Accessed June 2010); Ishak, K., Baptista, A., Bianchi, L., Histological grading and staging of chronic hepatitis (1995) J. Hepatol, 22, pp. 696-699; Knodell, R.G., Ishak, K.G., Black, W.C., Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis (1981) Hepatology, 1, pp. 431-435; Powell, S.R., The antioxidant properties of zinc (2000) J. Nutr, 130, pp. 1447S-1454S; Loguercio, C., Federico, A., Oxidative stress in viral and alcoholic hepatitis (2003) Free Radic. Biol. Med, 34, pp. 1-10; Mocchegiani, E., Muzzioli, M., Giacconi, R., Zinc and immunoresistance to infection in aging: New biological tools (2000) Trends Pharmacol. Sci, 21, pp. 205-208; Radhakrishnan, R., Walter, L.J., Hruza, A., Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography (1996) Structure, 4, pp. 1453-1463; Moriyama, M., Matsumura, H., Fukushima, A., Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease (2006) Dig. Dis. Sci, 51, pp. 1967-1977; Himoto, T., Hosomi, N., Nakai, S., Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease (2007) Scand. J. Gastroenterol, 42, pp. 1078-1087; Anand, B.S., Velez, M., Assessment of correlation between serum titers of hepatitis C virus and severity of liver disease (2004) World J. Gastroenterol, 10, pp. 2409-2411; Mohamed, A.A., Sabry, N.A., Abbassi, M.M., Ibrahim, W., Ali-Eldin, Z.A., Vitamin D Levels in Egyptian HCV Patients (Genotype 4) Treated with Pegylated Interferon (2013) Acta Gastro-enterologica, 17, pp. 38-44; Poynard, T., Marcellin, P., Lee, S.S., Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) (1998) Lancet, 352, pp. 1426-1432; Meram, I., Sirmatel, F., Ahi, S., Tarakcioglu, M., Plasma copper and zinc levels in chronic viral hepatitis (2004) Saudi. Med. J, 25, pp. 1066-1069; Nagamine, T., Takagi, H., Takayama, H., Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b (2000) Biol. Trace. Elem. Res, 75, pp. 53-63; Hepburn, M.J., Hepburn, L.M., Cantu, N.S., Lapeer, M.G., Lawitz, E.J., Differences in treatment outcome for hepatitis C among ethnic groups (2004) Am. J. Med, 117, pp. 163-168; Ishikawa, T., Can zinc enhance response interferon therapy for patients with HCV-related liver disease? (2012) World J. Gastroenterol, 18, pp. 3196-3200; Holmes, J.A., Desmond, P.V., Thompson, A.J., Redefining baseline demographics: The role of genetic testing in hepatitis C virus infection (2011) Clin. Liver. Dis, 15, pp. 497-513; Coble, Y.D., Vanreen, R., Schulert, A.R., Zinc levels and blood enzyme activities in Egyptian male subjects with retarded growth and sexual development (1966) Am. J. Clin. Nutr, 19, pp. 415-421; (2006), FAO Food And Nutrition Paper. The double burden of malnutrition: Case studies from six developing countries. In, FAO Food And Nutrition Paper. Rome: Food And Agriculture Organization Of The United Nations
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty of Biotechnology Research Paper